Lilly CEO Says Weight-Loss Drug Will Be Off Shortage Soon (1)

Eli Lilly & Co. expects its blockbuster weight-loss drug to officially come out of shortage in the US in the coming days, the company’s chief executive officer said, threatening the billion-dollar industry of copycat versions of the in-demand drugs.

Lilly’s drug, sold for weight loss as Zepbound, will cease to be in shortage “very soon,” CEO David Ricks said in an interview in Paris on Thursday. “I think actually today or tomorrow we plan to exit that process.”

Multiple dosages of the drug, also marketed for diabetes under the brand name Mounjaro, have been on the Food and Drug Administration ...